Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Portfolio Pulse from
Myriad Genetics has partnered with INTERLINK Care Management to improve access to its MyRisk hereditary cancer test for CancerCARE for Life members, potentially reaching over one million individuals.
February 06, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics has entered into a partnership with INTERLINK Care Management to expand access to its MyRisk hereditary cancer test, potentially reaching over one million individuals in the CancerCARE for Life network.
The partnership with INTERLINK Care Management is likely to increase the adoption of Myriad Genetics' MyRisk test by providing access to over one million individuals. This could lead to increased revenues and market presence for Myriad Genetics, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90